ClinicalTrials.gg
CompletedNCT04652401EqualVENTUpdated Feb 9, 2022

Quality of Life in Ventilator-dependant Neuromuscular Patients

An observational study in Neuromuscular Diseases, Respiration, Artificial and Tracheostomy, sponsored by Centre d'Investigation Clinique et Technologique 805. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2022-02-09.

Sponsored by Centre d'Investigation Clinique et Technologique 805 · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Cross-sectional
Enrollment
119
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Neuromuscular Diseases by Centre d'Investigation Clinique et Technologique 805 — none open to participants now, none under way, none of them phase 3. Neuromuscular Diseases · Centre d'Investigation Clinique et Technologique 805.

Enrollment
4th of 10
119 · median 89
Started
2020
the only one that year
Observational
10 of 23
none open now
Registered
23rd of 23
by date

Among the 23 studies in Neuromuscular Diseases by Centre d'Investigation Clinique et Technologique 805, this one is the 4th largest by enrollment of the 10 observational ones that give a count, is the only one that started in 2020, is one of 10 observational ones, and was the 23rd registered.

Neuromuscular Diseases

361 studies on the registry are indexed under Neuromuscular Diseases; 96 are open to participants now.

Browse Neuromuscular Diseases studies →

Open to participants now

None of the 23 studies in Neuromuscular Diseases by Centre d'Investigation Clinique et Technologique 805 is open now. The open studies under Neuromuscular Diseases, anywhere →

Where they have run

Who these studies take

Of the 69 Neuromuscular Diseases studies recruiting now, 39 (57%) set no upper age limit and 22 (32%) stop at 75 or younger; 35 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 23 studies in Neuromuscular Diseases by Centre d'Investigation Clinique et Technologique 805 as a file.
02

Study summary

This study aims at evaluating the quality of life of patients with slowly progressive neuromuscular disorders who are dependant on mechanical ventilation (daily usage ≥ 16h).

03

Conditions studied

  • Neuromuscular Diseases
  • Respiration, Artificial
  • Tracheostomy
  • Noninvasive Ventilation
  • Quality of Life
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with slowly progressive neuromuscular disease using home mechanical ventilation for at least 16 hours a day since at least one year. Patients may be ventilated via invasive or noninvasive interface.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with slowly progressive neuromuscular disorder (NMD), non walking
  • Patients dependant on mechanical ventilation (daily usage ≥ 16h) for at least 1 year before inclusion
  • Aged ≥ 18 yo
  • Consent for participation
  • Affiliated to a social security regime

Exclusion criteria

Exclusion Criteria:

  • Patients with medically non-stable NMD: fever, acute respiratory infection, organ decompensation
  • Patients with significant cognitive impairment (inability to read and/or incomprehension of questions)
  • Patients with fast-evolving neuromuscular disease
  • Patients declining to participate in the study
  • Patients under guardianship and/or trusteeship
  • Pregnant women
05

Study design

Observational model
Cohort
Time perspective
Cross-sectional
Enrollment
119 participants (actual)
Patient registry
No
06

What researchers measure

Primary outcomes

  1. Score of the Severe Respiratory Insufficiency questionnaire (SRI)

    Higher score represents better quality of life

    Time frame: 1 Day

  2. Score of the Quality of Life Measure for people with slowly progressive and genetic neuromuscular disease questionnaire (QoL-gNMD)

    Higher score represents better quality of life

    Time frame: 1 Day

07

Study locations

1 site
  • AFM Téléthon
    Évry, France
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Dec 2020 to primary completion in Dec 2021, 12 months.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 9, 2020
First posted
Dec 3, 2020
StartActual
Dec 2, 2020
Primary completionActual
Dec 7, 2021
CompletionActual
Dec 7, 2021
Last update
Feb 9, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 9, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04652401
Lead sponsor
Centre d'Investigation Clinique et Technologique 805
Collaborators
Fondation Garches, AFM Téléthon, FilNeMus
Responsible party
Sponsor
First posted
Dec 3, 2020
Start date
Dec 2, 2020
Primary completion
Dec 7, 2021
Completion
Dec 7, 2021
Last update
Feb 9, 2022

Study contacts

Mathieu Delorme, MSc
principal investigator · Université Paris-Saclay, UVSQ, ERPHAN, 78000, Versailles, FRANCE
Frederic Lofaso, MD, PhD
study director · Université Paris-Saclay, UVSQ, ERPHAN, 78000, Versailles, FRANCE

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion